Aurelium’s success and rapid growth is due to its integrated SMART™ proteomics technology platforms that include optimized Functional proteomics.  These technology platforms coupled with the Company's established Drug Resistance Model Systems (or DRMS™) and surface-tagging method (STAG™) provided the raw materials for Aurelium's production of therapeutically relevant targets and biomarkers. Validated targets are developed into two classes of Multiple Marker Diagnostics (or MMD™), including DNA and Protein based diagnostics.  The Company’s array of robust diagnostic tests are platform independent and can be developed for any Real-time PCR or Immunologic detection platforms.